<HEAD><TITLE>Case Conference: Enoxaparin</TITLE></HEAD><BODY BGCOLOR="#ffffff"><TABLE><TR><TD WIDTH="91"></TD><TD WIDTH="336"><IMG SRC="tdot.gif" WIDTH="1" HEIGHT="1" HSPACE="0" VSPACE="20"><BR><I>What laboratory tests  reflect the anticoagulant activity of enoxaparin?</I><BR><IMG SRC="tdot.gif" WIDTH="1" HEIGHT="1" HSPACE="0" VSPACE="20"><BR><FONT SIZE="+1">C</FONT>onventional laboratory tests such as the protime, activated partial thromboplastin time, and  thrombin  time are not affected by low molecular weight heparin.  Like  unfractionated heparin, low molecular weight heparin exerts its anticoagulant effect primarily by inhibiting activated factor X (Xa) and thrombin (IIa), but with proportionately more activity against Xa.<BR><IMG SRC="tdot.gif" WIDTH="1" HEIGHT="1" HSPACE="0" VSPACE="20"><BR>REFERENCES<BR><IMG SRC="tdot.gif" WIDTH="1" HEIGHT="1" HSPACE="0" VSPACE="10"><BR>1.  Weitz JI.  Low-molecular weight heparins [review]<I>New England Journal of Medicine</I> 1997;337(10):688-98.<BR><IMG SRC="tdot.gif" WIDTH="1" HEIGHT="1" HSPACE="0" VSPACE="10"><BR>2.   Horlocker-TT, Heit-JA.  Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthestic management [review].  <I>Anesth Analg</I>  1997;85:874-85.<BR><IMG SRC="tdot.gif" WIDTH="1" HEIGHT="1" HSPACE="0" VSPACE="30"><BR><A HREF="enoxaparin1.html#questions"><FONT="-2">BACK</FONT></A></TD></TR></TABLE></BODY></HTML>